Introduction {#sec1}
============

Age-related macular degeneration (AMD) is the leading cause of severe central visual loss in the elderly.[@bib1], [@bib2] Its prevalence is estimated to be 13%--29.7% in people over 55 years.[@bib3] One of the main reasons of visual loss in AMD is choroidal neovascularization (CNV),[@bib4] which occurs in the neovascular form of the disease. Consequently, most available treatment modalities are directed against this advanced neovascular stage of disease.[@bib5], [@bib6]

In addition to well-known risk factors such as aging, smoking, sunlight exposure, and family history,[@bib7], [@bib8] many authors have addressed the role of genetics and special alleles in the pathogenesis of AMD as well as its clinical features.[@bib9] Identification of exact genes and their either offensive or protective role in this disease can clearly alter the therapeutic approaches for AMD.

Complement factor H gene (CFH) Y402H variant on 1q32 and several adjacent alleles on 10q26 (loc387715/ARMS2 gene and HtrA serine peptidase 1 gene) have been reported to be strongly associated with neovascular AMD. There are also some conflicting reports about the association of these alleles and some clinical and angiographic features of AMD.[@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19]

In this study, we investigated the frequency of some of the previously reported alleles associated with neovascular AMD as well as the association between these alleles and clinical features of AMD.

Methods {#sec2}
=======

We enrolled 44 patients who were referred to the Retina Service of Farabi Eye Hospital of Tehran University of Medical Sciences (TUMS) between February to April 2014. The study protocol was approved by the review board of Farabi Eye Hospital and the Committee of Medical Ethics of TUMS. Moreover, informed written consent was obtained from all patients.

After recording demographic data (age at the time of diagnosis, gender, family history) and patient medical history, a complete bilateral ophthalmic examination was performed for each patient as follows: examining best corrected visual acuity (BCVA) (using snellen chart and then converting it to logMAR), anterior segment examination, intraocular pressure measurement, and full dilated fundoscopy. The inclusion criteria were presence of neovascular AMD at least in one eye which was defined by having CNV, subretinal hemorrhage, fibrosis, and angiographic documentation of the CNV at the time of diagnosis (using Heidelberg fluorescein angiography) or before entering the study. All the patients with suspicious polypoidal choroidal vasculopathy and retinal angiomatous proliferation were evaluated by indocyanine green (ICG) angiography and excluded from the study if the diagnosis was confirmed. Patients with pathologic myopia, angioid streaks, choroidal rupture, any history of retinal laser treatment, or any disease condition other than AMD which can cause CNV and any history of intravitreal pharmacologic injection treatment were excluded. All patients were treatment naïve and no previous treatment had been performed.

Presence of dry or wet type AMD in the other eye was also recorded. In patients with bilateral neovascular involvement, the eye with a worse clinical state was chosen for statistical analysis. All the patients or their information profile including fluorescein angiography were reviewed at least by 2 retinal sub specialists.

Genetic analysis {#sec2.1}
----------------

15 ml of peripheral blood samples from each 44 of the patients nAMD was collected by antecubital venipuncture into ethylenediaminetetraacetic acid (EDTA)-containing tubes. After adding 10 ml of Red Cell Lysis Buffer and mixing completely, samples were centrifuged for 10 min at 1,300 g (3--30k Refrigerated Centrifuge, Sigma, Germany). After discarding supernatant and adding 10 ml Phosphate Buffered Salts (PBS Tablets; TAKARA BIO INC., Japan), cell pellets were suspended again and centrifuged for 8 min at 1,200 g for washing, twice.

Harvested Cells were used for genomic DNA extraction with a DNA blood kit (QIAamp^®^ DNA Blood Mini kit; Qiagen, Germany) according to the manufacturer\'s protocol (which was briefly, 20 μl proteinase K was added to the 200 μl of cells plus 200 μl lysis buffer. After adding 200 μl ethanol and vortexing, samples were transferred to the columns and centrifuged at 6000 g for 1 min. Then 500 μl washing buffer was added and centrifuged at 20,000 g for 3 min. Finally, 20 ng of puriﬁed DNA was used for genotyping analysis). For genetic analysis Sequenom iPLEX system technology was used (Sequenom, San Diego, CA, USA) to detect AMD related SNPs in the following order: rs203674, rs800292, rs35507625, rs572515, rs1061147, rs7529589, rs1061170, rs12038333, rs2274700, for CFH gene on chromosome 1 and rs10664316, rs11200638, rs2672598 for LOC387715/ARMS2/HTRA1 gene on chromosome 10.

Statistical analysis {#sec2.2}
--------------------

Statistical analysis was performed using SPSS 16 software (SPSS, Inc., Chicago,IL). Prescriptive tests were used for displaying the magnitude of each allele, gender distribution, and age (mean ± SD). Visual acuities were converted to the logarithm of the minimal angle of resolution (logMAR) units and were categorized into 2 groups: logMAR≤1 (snellen acuity ≥ 20/200) as better visual acuity (VA) and logMAR\>1 (snellen visual acuity \<20/200) as worse VA. Fisher exact test used to evaluate the correlation between VA and different alleles. Kruskal--Wallis test was also used for comparison between age at the time of diagnosis and different alleles. p \< 0.05 was considered statistically significant. The association between SNPs and age groups (equal or less than 75 years old versus more than 75 years old), sex, and laterality (disease affecting one eye or both eyes of the patients) have been assessed by using chi square test. The Hardy--Weinberg Equilibrium was calculated for each SNP, and all the SNPs were in Hardy--Weinberg Equilibrium.

Results {#sec3}
=======

44 eligible patients entered the study. 28 patients were male (63.6%), and 16 patients were female (36.4%). The mean age of patients was 74.63 ± 7.55 years (ranged from 58 to 90 years). Mean VA of patients was 1.7 ± 0.8 logMAR. The frequencies of all SNPs among patients are detailed in [Table 1](#tbl1){ref-type="table"}. The most frequent SNP among study patients was rs1061147 with 100% frequency. The least common was rs2672598 with a frequency of 52.27%.

Only the allele rs800292 of CFH locus on 1q32 was associated with VA better than 20/200 (p value = 0.034). Mean VA of the patients with this allele was 0.1 ± 0.12 logMAR. The frequency of this allele was 77.27% (34 patients). There was no significant correlation between any of alleles and VA worse than 20/200.

Fifteen patients had bilateral neovascular AMD (34.09%). There was no significant difference between allele frequencies between bilateral and unilateral AMD groups.

Discussion {#sec4}
==========

AMD is one of the most common causes of blindness in the elderly worldwide. Multiple risk factors have been proposed in the pathogenesis of this disease. The role of genetic factors in the etiology of AMD is documented, and several predisposing SNPs have been proposed to be associated with AMD ([Table 3](#tbl3){ref-type="table"}).[@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30] The most important SNPs are CFH gene on chromosome 1 and LOC387715/ARMS2/HTRA1 on chromosome 10.[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib23] CFH gene expression affects the binding affinity of CFH glycoprotein to C-reactive protein and heparin and regulates its anti-inflammatory effects.[@bib17] The exact mechanism of action of the LOC387715 gene product is not clearly understood.[@bib29] Allele frequency of these genes was between 61 and 94% in AMD patients in some studies.[@bib9], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib24] However, the frequency is not constant across different ethnic groups. In some reports of Chinese and Turkish population samples, the frequencies are lower than what has been reported in other ethnic groups, especially Caucasians.[@bib23], [@bib28] In this study, the frequencies of some of the previously reported SNPs in neovascular AMD patients were evaluated in a sample of an Iranian population.

In our case series, rs1061147 from CFH genes on 1q32 was the most common allele (100% frequency rate), and the least common SNP was rs2672598 from loc387715/ARMS2/HTRA1 on 10 q26 (frequency rate: 52.27%). All the other SNPs\' frequencies ranged from 52.27% to 99.9% ([Table 2](#tbl2){ref-type="table"}).

These frequencies are consistent with some of the previous studies that reported similar findings in their own ethnic populations.[@bib9], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib24] In the Andreoli cohort study, similar frequencies for both CFH and LOC-387715/ARMS2/HRTA1 SNPs[@bib9] were found. However, in some other ethnic populations, the reported frequencies were different. For example, Chen et al. reported a frequency of 5.8% for CFH genes in their Chinese AMD patients.[@bib23] In the Iranian population, Babanejad et al.[@bib25] reported the same frequency for rs800292 C allele, but the reported frequencies for rs2274700 and rs1061170 (either C allele, rare allele and heterozygous allele) was different from our study. Additionally, in Nazari Khanamiri et al.'s case--control study,[@bib24] Y402H and A69S polymorphisms were strongly associated with AMD in a sample of the Iranian population.[@bib24]

Among 12 alleles assessed in this study, only rs800292 of CFH SNPs was associated with VA better than 20/20 (p value 0.034). This is not in accordance with previously published results by Andreoli et al.[@bib9] which found LOC387715/ARMS2 rs10664316 and HTRA1 rs1049331 as the SNPs which were associated with protection from worse visual acuity at the time of diagnosis.

We also did not find any association between assessed alleles and age or gender. Some studies reported rs11200638 and rs10490924 from LOC387715/ARMS2 to be associated with earlier age of onset of AMD.[@bib9], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23]

In this case series, there was no difference between unilateral or bilateral involvement considering SNP frequencies, but it has been reported in previous trials that CFH genes also rs11200638 cause susceptibility to bilateral AMD involvement [@bib26], [@bib27].

This is one of the few studies which has evaluated AMD genetics in an Iranian population.[@bib24], [@bib25] Limitations of this study include a lack of a control group and small sample size.

In conclusion, AMD seems to have a strong genetic pathogenesis which may influence its clinical features. Further studies which include a larger sample size, a control group, and careful follow-up will clarify more details of this multifactorial prevalent disease pathogenesis.
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###### 

Statistical association of each SNP with age, sex,VA, and laterality.

  Gene              SNP          Age (≤75 years vs \> 75 years) (p value)   Sex (p value)   Better VA (better than 20/200) (p value)   Laterality (bilateral or unilateral) (p value)
  ----------------- ------------ ------------------------------------------ --------------- ------------------------------------------ ------------------------------------------------
  CFH               rs203674     0.994                                      0.265           0.513                                      0.330
  CFH               rs572515     0.820                                      0.561           0.773                                      0.456
  CFH               rs800292     0.590                                      0.886           0.034                                      0.764
  CFH               rs1061147    0.800                                      0.977           0.444                                      0.822
  CFH               rs1061170    0.378                                      0.820           0.435                                      0.424
  CFH               rs2274700    0.555                                      0.197           0.772                                      0.672
  CFH               rs7529589    0.424                                      0.539           0.591                                      0.515
  CFH               rs12038333   0.185                                      0.208           0.247                                      0.522
  CFH               rs35507625   0.985                                      0.892           0.326                                      0.342
  LOC387715/ARMS2   rs11200638   0.672                                      0.472           0.262                                      0.635
  LOC387715/ARMS2   rs10664316   0.966                                      0.773           0.342                                      0.514
  HTRA1             rs2672598    0.633                                      0.680           0.355                                      0.625

SNP: single nucleotide polymorphisms, VA: visual acuity, CFH: complement factor H, ARMS2: age related maculopathy susceptibility 2 gene, HTRA1: HtrA serine peptidase 1 gene.

###### 

Single nucleotide polymorphism analyzed in 44 nonvascular AMD patients.

  Gene              SNP          Base change[a](#tbl2fna){ref-type="table-fn"}   Total frequency (%)   Frequency of homozygous common allele   Frequency of heterozygous allele   Frequency of homozygous rare allele
  ----------------- ------------ ----------------------------------------------- --------------------- --------------------------------------- ---------------------------------- -------------------------------------
  CFH               rs203674     C→A                                             90.90%                0.365                                   0.414                              0.219
  CFH               rs572515     T→C                                             93.18%                0.341                                   0.414                              0.243
  CFH               rs800292     C→A                                             77.27%                0.735                                   0.26                               0
  CFH               rs1061147    A→C                                             100%                  0.509                                   0.372                              0.117
  CFH               rs1061170    C→T                                             70.45%                0.387                                   0.483                              0.129
  CFH               rs2274700    C→T                                             95.45%                0.547                                   0.285                              0.166
  CFH               rs7529589    T→C                                             88.63%                0.358                                   0.512                              0.128
  CFH               rs12038333   G→A                                             90.90%                0.35                                    0.45                               0.2
  CFH               rs35507625   del                                             93.18%                0.829                                   0.121                              0.04
  LOC387715/ARMS2   rs11200638   A→G                                             63.63%                0.5                                     0.357                              0.142
  LOC387715/ARMS2   rs10664316   Del AT                                          86.36%                0.552                                   0.342                              0.105
  HTRA1             rs2672598    G→A                                             52.27%                0.565                                   0.434                              0

CFH = complement factor H gene, ARMS2 = age-related maculopathy susceptibility 2 gene, HTRA1 = HtrA serine peptidase 1 gene, SNP = single nucleotide polymorphism.

Base change is written common allele \> rare allele.

###### 

Effect of SNPs on clinical findings of AMD patients in different studies.

  Year   Author                     Countery    Study design           Mean age                Male/female ratio   Earlier age of onset                                 Better visual acuity (better than 20/200)   Worse visual acuity           Bilateral involvement         Larger CNV size
  ------ -------------------------- ----------- ---------------------- ----------------------- ------------------- ---------------------------------------------------- ------------------------------------------- ----------------------------- ----------------------------- -----------------
  2014   This study                 Iran        Case series            74.63 ± 7.55            63.6%/36.4%         Non                                                  rs800292                                    Non                           Non                           Non
  2009   Andreoli[@bib9]            USA         Retrospective cohort   72.5 ± 7.8              46.4%/53.6%         rs11200638 and rs10490924                            rs10664316 and rs1049331                    Non                           Non                           rs11200638
  2011   Hiroaki Bessho[@bib31]     Japan       Retrospective cohort   76 ± 6                  85.4%/14.6          Non                                                  Non                                         Non                           Non                           rs10490924
  2008   Leveziel N[@bib19]         France      Cohort                 72.8 ± 8.8              32%/68%             rs11200638 and rs10490924                            Non                                         Non                           Non                           Non
  2007   Brantley MA[@bib20]        USA         Retrospective cohort   79.8                    36%/64%             rs11200638 and rs10490924                            Non                                         Non                           Non                           rs1061170
  2009   Brantle MA[@bib21]         USA         Case-control           78.9 ± 8.1              35.6%/64.8%         rs11200638 and rs10490924                            Non                                         Non                           Non                           Non
  2008   Shuler RK[@bib22]          USA         Case-control           76.4                    33.6%/66.4%         rs11200638 and rs10490924                            Non                                         Non                           Non                           Non
  2011   Chen H[@bib32]             USA         Cohort                 75.1 ± 9.0              46.4%/53.6%         Non                                                  Non                                         Non                           rs11200638/rs10490924         Non
  2009   Pai AS[@bib27]             Australia   Cross-sectional        73.9 ± 8.3/80.4 ± 7.9   34.6%/65.4%         Non                                                  Non                                         Non                           CFH CC genes                  Non
  2007   Shuler RK[@bib30]          USA         Cross-sectional        75.8 ± 8.6              44.2%/55.8%         rs10490924 and CFH (T1277C at rs1061170, or Y402H)   Non                                         Non                           Non                           Non
  2010   Nicolas Leveziel[@bib33]   France      Cohort                 80.6 ± 5.8              33.4%/66.6%         Non                                                  Non                                         rs10490924 pp/rs10611710 pp   rs10490924 pp/rs10611710 pp   Non

SNP: single nucleotide polymorphisms, AMD: age related macular degeneration, CNV: choroidal neovascularization, CFH: complement factor H.
